



UCB S.A. Allée de la Recherche 60, B-1070 Brussels (Belgium)

Press Release

Significant acceptances by SCHWARZ shareholders for UCB tender offer

Brussels, December 11, 2006 – The final total of acceptances received by midnight on Friday December 8 will be available on Thursday December 14, 2006. Acceptances already counted show UCB has received tenders in excess of 76% of the fully diluted share capital of SCHWARZ PHARMA (“SCHWARZ”). As is required in such a transaction in Germany, the offer will be extended for an additional two weeks. An announcement concerning this additional acceptance period will also be made this coming Thursday.

Roch Doliveux, CEO of UCB, said, "I am delighted with the results of the tender offer so far. The current level of acceptances already received from SCHWARZ shareholders will allow the two companies to capture significant benefits of this exciting business combination, on which our resources will be focused. I thank shareholders for their support in building UCB as the next generation biopharmaceutical leader."

About UCB

UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology – UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium.

Inquiries, please contact

Jean-Christophe Donck

Vice President, Corporate Communications & Investor Relations

Phone +32 2 559 9346